Clinical Trials Browser

Breast Neoplasms

NCT02661932 2025-01-31

Brovale

Phase 4 Completed

65 enrolled

Breast

Breast Neoplasms

NCT03355157 2024-10-01

PADMA

Phase 4 Completed

130 enrolled

Breast

Breast Neoplasms, Patient Acceptance of Health Care

NCT05809024 2023-04-12

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Phase 4 Recruiting

100 enrolled

Breast

Locally Advanced Breast Cancer

NCT01035099 2022-12-13

RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF

Phase 4 Completed

41 enrolled 14 charts

Breast

Breast Neoplasms, Infertility

NCT03948568 2022-09-30

REaCT-RETT

Phase 4 Completed

262 enrolled

Breast

Breast Neoplasms

NCT02679755 2022-07-27

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

Phase 4 Completed

252 enrolled 15 charts

Breast

Breast Neoplasms

NCT03220178 2022-01-06

PRECYCLE

Phase 4 Terminated

532 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04137640 2021-07-20

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

Phase 4 Not yet recruiting

152 enrolled

Breast

Breast Neoplasms

NCT00688909 2021-06-09

REAL

Phase 4 Completed

261 enrolled 13 charts

Breast

Breast Neoplasms

NCT03238703 2018-12-27

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Phase 4 Withdrawn

Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT01612871 2018-03-05

MIRHO

Phase 4 Completed

39 enrolled

Breast

Breast Neoplasms

NCT01127295 2018-03-02

PHACS

Phase 4 Completed

2,000 enrolled

Breast

Breast Neoplasms

NCT00237133 2017-02-24

PREDICT

Phase 4 Completed

112 enrolled

Breast

Breast Neoplasms

NCT01908556 2013-07-25

PreFace

Phase 4 Unknown

3,545 enrolled

Breast

is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.

NCT01553903 2013-06-04

OXYTAM

Phase 4 Completed

29 enrolled

Breast

Breast Neoplasms

NCT00014638 2013-02-21

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 4 Completed

Breast

Breast Neoplasms

NCT00241046 2012-04-19

Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment

Phase 4 Terminated

13 enrolled

Breast

Breast Neoplasms

NCT00171847 2010-03-31

eLEcTRA

Phase 4 Terminated

93 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00237224 2009-11-19

Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole

Phase 4 Completed

40 enrolled

Breast

Breast Neoplasms

Clinical Trials

Roll-over Study to Allow Continued Access to Ribociclib

Brovale

PADMA

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF

REaCT-RETT

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

PRECYCLE

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

REAL

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

MIRHO

PHACS

PREDICT

PreFace

OXYTAM

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment

eLEcTRA

Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole